Complications of peripheral angioplasty access

Original title: Access Site Complications After Peripheral Vascular Interventions. Incidence, Predictors, and Outcomes. Reference: Daniel Ortiz et al. Circ Cardiovasc Interv. 2014 Nov 11. Epub ahead of print.

 

Hematomas and pseudoaneurysms are the most common complications of peripheral angioplasty, though its incidence and risk factors are unclear. A retrospective analysis was performed in 22226 patients receiving peripheral angioplasty between 2007 and 2013 at several centers. The primary end points included the incidence and complication predictors related to vascular access, post procedure length of stay and mortality at 30 days and one year. Access complications occurred in 936 procedures (3.5%). Of these, 74.4% were minor, 9.7% were moderate requiring transfusion, 5.4% were moderate requiring thrombin injection and 10.5% were severe complications requiring surgery.

Predictors of complications related to access were age (>75 years), female gender, access different to femoral, introducer >6 Fr, use of thrombolytics, arterial dissection, fluoroscopy time     >30 minutes, urgent indication and the absence of percutaneous closure devices procedure. In patients who had complications access, hospital stay was significantly higher (1.2 ± 1.6 versus 1.9 ± 1.9 days; p = 0.002) and in which the complication was severe, an increased mortality was observed at 30 days (6.1% versus 1.4%; p <0.001). In those which complication was moderate but requiring transfusion, mortality was higher per year (12.1% versus 5.7%, p <0.001).

Conclusion

Several factors independently predict the risk of complications of vascular access in patients receiving peripheral angioplasty. The appropriate use of anti-thrombotic and vascular closure devices could improve results.

Editorial comment

This issue, which has been widely analyzed in coronary angioplasty, did not have much data for peripheral angioplasty. Two of the most useful resources in coronary angioplasty as radial access and use of bivalirudin, have technical limitations or insufficient evidence in the peripheral angioplasty. The radial access may be useful in selected cases of renal angioplasty, iliac primitive or carotid, but not much further. Bivalirudin has some evidence in carotid angioplasty but not in other territories.

SOLACI

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...